Last reviewed · How we verify
Quetiapine and Topiramate
Quetiapine and Topiramate is a Atypical antipsychotic + anticonvulsant mood stabilizer combination Small molecule drug developed by University of Cincinnati. It is currently FDA-approved for Bipolar disorder (off-label combination), Treatment-resistant depression (off-label combination), Schizophrenia with mood instability (off-label combination). Also known as: Topiramate.
This combination uses quetiapine's dopamine and serotonin antagonism for antipsychotic/mood effects alongside topiramate's sodium channel blockade and carbonic anhydrase inhibition for mood stabilization and anticonvulsant activity.
This combination uses quetiapine's dopamine and serotonin antagonism for antipsychotic/mood effects alongside topiramate's sodium channel blockade and carbonic anhydrase inhibition for mood stabilization and anticonvulsant activity. Used for Bipolar disorder (off-label combination), Treatment-resistant depression (off-label combination), Schizophrenia with mood instability (off-label combination).
At a glance
| Generic name | Quetiapine and Topiramate |
|---|---|
| Also known as | Topiramate |
| Sponsor | University of Cincinnati |
| Drug class | Atypical antipsychotic + anticonvulsant mood stabilizer combination |
| Target | D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Quetiapine is an atypical antipsychotic that blocks D2 dopamine and 5-HT2A serotonin receptors, used for psychosis and bipolar disorder. Topiramate is an anticonvulsant that blocks voltage-gated sodium channels and inhibits carbonic anhydrase, providing mood-stabilizing and neuroprotective effects. The combination leverages both agents' psychiatric benefits, though this is an off-label polypharmacy approach rather than a single fixed-dose entity.
Approved indications
- Bipolar disorder (off-label combination)
- Treatment-resistant depression (off-label combination)
- Schizophrenia with mood instability (off-label combination)
Common side effects
- Sedation/somnolence
- Weight gain
- Cognitive impairment
- Dizziness
- Dry mouth
- Paresthesias (topiramate)
Key clinical trials
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Efficacy Study of Quetiapine Plus Topiramate for Reducing Cannabis Consumption and Bipolar Mania (PHASE4)
- Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults (PHASE4)
- Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism (PHASE4)
- Juvenile Bipolar Disorder Outpatient Program (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quetiapine and Topiramate CI brief — competitive landscape report
- Quetiapine and Topiramate updates RSS · CI watch RSS
- University of Cincinnati portfolio CI
Frequently asked questions about Quetiapine and Topiramate
What is Quetiapine and Topiramate?
How does Quetiapine and Topiramate work?
What is Quetiapine and Topiramate used for?
Who makes Quetiapine and Topiramate?
Is Quetiapine and Topiramate also known as anything else?
What drug class is Quetiapine and Topiramate in?
What development phase is Quetiapine and Topiramate in?
What are the side effects of Quetiapine and Topiramate?
What does Quetiapine and Topiramate target?
Related
- Drug class: All Atypical antipsychotic + anticonvulsant mood stabilizer combination drugs
- Target: All drugs targeting D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
- Manufacturer: University of Cincinnati — full pipeline
- Therapeutic area: All drugs in Psychiatry / Neurology
- Indication: Drugs for Bipolar disorder (off-label combination)
- Indication: Drugs for Treatment-resistant depression (off-label combination)
- Indication: Drugs for Schizophrenia with mood instability (off-label combination)
- Also known as: Topiramate
- Compare: Quetiapine and Topiramate vs similar drugs
- Pricing: Quetiapine and Topiramate cost, discount & access